Boehringer Ingelheim agreed with the U.S. administration to invest $10 billion in U.S. R&D, manufacturing and operations through 2028 and to participate in the TrumpRx.gov direct‑purchase platform aimed at lowering medicine costs. The company said the deal includes an exemption from potential Section 232 tariffs and a $1 billion dedicated capital expenditure commitment. Boehringer framed the move as expanding U.S. manufacturing capacity and improving supply‑chain resilience while aligning with administration goals on affordability. Company statements and CEO Jean‑Michel Boers’ comments provided the details.